Request for Trading Halt for Antisense Therapeutics Limited
In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).
In requesting the trading halt, the Company provides the following information:
? The trading halt is necessary as the Company expects to make an announcement to the
market in relation to reporting on the ATL1103 clinical trial;
? Unless otherwise requested by the Company, the Company requests the trading halt to
remain in place until the announcement is made to the market; and
? The Company is not aware of any reason why the trading halt should not be granted or of
any other information necessary to inform the market about the trading halt.
results for atl1103...
-
- There are more pages in this discussion • 233 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
